2015
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2015, 72: 1037-1044. PMID: 26351969, PMCID: PMC4811029, DOI: 10.1001/jamapsychiatry.2015.1472.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderSymptom-onset dosingSerotonin reuptake inhibitorsDays of mensesSSRI withdrawalSymptom onsetSymptomatic daysMenstrual cycleClinical trialsDysphoric disorderOutcome measuresScale scoreSRI treatmentTreatment of PMDDClinical Global Impression ScaleAbrupt treatment cessationDepressive Symptomatology-ClinicianTotal DRSP scoresSecondary outcome measuresPrimary outcome measureGlobal Impression ScaleIDS-C scoresUniversity Medical CenterSertraline hydrochlorideBeginning of menses
2012
Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5
Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I, Yonkers KA. Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. American Journal Of Psychiatry 2012, 169: 465-475. PMID: 22764360, PMCID: PMC3462360, DOI: 10.1176/appi.ajp.2012.11081302.Peer-Reviewed Original ResearchCriteria for Premenstrual Dysphoric Disorder: Secondary Analyses of Relevant Data Sets
Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for Premenstrual Dysphoric Disorder: Secondary Analyses of Relevant Data Sets. JAMA Psychiatry 2012, 69: 300-305. PMID: 22393222, PMCID: PMC3370334, DOI: 10.1001/archgenpsychiatry.2011.1368.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderDays of mensesDSM-IVPMDD symptomsDysphoric disorderMain outcome measuresOptimal cutoff pointNumber of symptomsSymptomatic periodMenstrual cycleProspective surveyOutcome measuresPerimenstrual symptomsPsychiatric disordersMore symptomsAffective symptomsCutoff pointPhysical symptomsPremenstrual phaseSecondary analysisSymptomsProblematic symptomsClinical settingDepressed moodCohort
2008
Premenstrual syndrome
Yonkers KA, O'Brien P, Eriksson E. Premenstrual syndrome. The Lancet 2008, 371: 1200-1210. PMID: 18395582, PMCID: PMC3118460, DOI: 10.1016/s0140-6736(08)60527-9.Peer-Reviewed Original ResearchConceptsSevere premenstrual syndromePremenstrual dysphoric disorderPremenstrual syndromeSerotonin reuptake inhibitorsGonadal hormone levelsGonadotropin-releasing hormoneOral contraceptivesReuptake inhibitorsBreast tendernessSerotonergic synapsesReproductive ageHormone levelsDysphoric disorderLuteal phaseOvary axisMost womenOvarian cyclicityBehavioral symptomsDepressed moodSymptomsMood swingsSomatic complaintsPhysical discomfortWomenDaily activities
2005
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder. Obstetrics And Gynecology 2005, 106: 492-501. PMID: 16135578, DOI: 10.1097/01.aog.0000175834.77215.2e.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPlacebo groupSymptom scoresDysphoric disorderNew low dose oral contraceptiveLow-dose oral contraceptivesBehavioral symptom scoresActive treatment groupDaily symptom scoresPhysical symptom scoresEthinyl estradiol groupInactive pillsOral contraceptivesEstradiol groupClinical trialsEthinyl estradiolTreatment cyclesTotal Daily RecordI. EfficacyDrospirenoneSymptomsPill formulationDisordersOCP formulationsPlaceboPretreatment pattern of symptom expression in premenstrual dysphoric disorder
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal Of Affective Disorders 2005, 85: 275-282. PMID: 15780697, DOI: 10.1016/j.jad.2004.10.004.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderPMDD symptomsMenstrual cycleDysphoric disorderPatient variabilityIntermittent dosing strategyOnset of menstruationDSM-IV criteriaPatients' durationAnxiety/tensionSertraline treatmentDRSP scoresPatient daysDosing strategiesSevere symptomsDay 2SymptomsTreatment studiesPretreatment patternAnger/irritabilityMood swingsMore daysWomenSymptom expressionTreatment implications
2003
Premenstrual disorders: bridging research and clinical reality
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Archives Of Women's Mental Health 2003, 6: 287-292. PMID: 14628181, DOI: 10.1007/s00737-003-0026-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultConnecticutDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersFemaleHumansPatient Acceptance of Health CarePatient SelectionPremenstrual SyndromePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSelf-AssessmentSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeConceptsPremenstrual dysphoric disorderPremenstrual symptomsTreatment resultsBrief Patient Health QuestionnaireConcurrent psychiatric conditionsOb-gyn settingsStatistical Manual IV criteriaSerotonin reuptake inhibitorsUsual care settingsPatient Health QuestionnaireMinor depressive disorderActual clinical practiceTypes of symptomsEligible womenPatient characteristicsReuptake inhibitorsOpen trialSymptomatic subgroupCurrent comorbidityIV criteriaClinical trialsDepressive disorderHealth QuestionnaireTypical patientDysphoric disorder
2001
Venlafaxine in the treatment of premenstrual dysphoric disorder.
Freeman E, Rickels K, Yonkers K, Kunz N, McPherson M, Upton G. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics And Gynecology 2001, 98: 737-44. PMID: 11704162, DOI: 10.1016/s0029-7844(01)01530-7.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderDaily symptom reportsTreatment of premenstrual dysphoric disorderDysphoric disorderHamilton Rating Scale for DepressionPremenstrual dysphoric disorder treatmentDSR scoresEfficacy of long-term maintenance treatmentSafety of venlafaxineFlexible-dose trialNew-generation antidepressantsLong-term maintenance treatmentDouble-blind treatmentTreatment cyclesPremenstrual symptom scoresVenlafaxine doseVenlafaxine treatmentSymptom reductionSymptom remissionInhibit serotoninNorepinephrine reuptakePMDD symptomsVenlafaxineSymptom reportingCyclic disorder